Wordt geladen...
Intravenous immunoglobulins for the treatment of mild to moderate Alzheimer’s disease: a phase II, randomised, double-blind, placebo-controlled dose-finding trial
BACKGROUND: Three small trials have suggested effects of intravenous immunoglobulins (IVIG) on biomarkers and symptoms of mild-to-moderate Alzheimer’s disease (AD). We explored the safety, the effective dose, and the infusion interval for Octagam(®)10% in this patients’ group. METHODS: The study was...
Bewaard in:
| Gepubliceerd in: | Lancet Neurol |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4986921/ https://ncbi.nlm.nih.gov/pubmed/23375965 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1474-4422(13)70014-0 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|